Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma

Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy. 117 patients with invasive IPM...

Full description

Saved in:
Bibliographic Details
Published in:Heliyon 2024-10, Vol.10 (19), p.e38430, Article e38430
Main Authors: Ouyang, Yonghao, Liu, Pengpeng, Chu, Lihua, Xiao, Yi, Zhu, Hong, Qiang hao, Zhang, Caihua
Format: Article
Language:English
Subjects:
Chemotherapy
Invasive intraductal papillary-mucinous carcinoma (IPMC)
Prognostic
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3270-68b0c17170f7438bfee69caea43f3c9d79ed1fae5f5922cfe7f5ff5a0d35eafb3
container_end_page
container_issue 19
container_start_page e38430
container_title Heliyon
container_volume 10
creator Ouyang, Yonghao
Liu, Pengpeng
Chu, Lihua
Xiao, Yi
Zhu, Hong
Qiang hao
Zhang, Caihua
description Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy. 117 patients with invasive IPMC were included in The Surveillance, Epidemiology, and End Results (SEER) database. These patients were subsequently divided into two subgroups according to whether they received chemotherapy or not: the non-chemotherapy group (patients who did not receivechemotherapy, N = 58), the chemotherapy group (patients who received chemotherapy, N = 59). The overall survival (OS) and cancer specific survival (CSS) of two treatment groups were evaluated. Before adjusting for pathology grade, the Kaplan-Meier analysis showed that the difference of survival time is not significant between non-chemotherapy group and chemotherapy group (P > 0.05), but the land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group (P 
doi_str_mv 10.1016/j.heliyon.2024.e38430
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c0c802a938ba4342a5909e2d0d9879d5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405844024144611</els_id><doaj_id>oai_doaj_org_article_c0c802a938ba4342a5909e2d0d9879d5</doaj_id><sourcerecordid>3118836638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3270-68b0c17170f7438bfee69caea43f3c9d79ed1fae5f5922cfe7f5ff5a0d35eafb3</originalsourceid><addsrcrecordid>eNqFUk1v1DAQjRCIVqU_AZQjl2z9ESf2qaoqPlaqxAXOlmOPG6-SONjOor3zw3HYbemeOHk0fvNm5s0rivcYbTDCzc1u08PgDn7aEETqDVBeU_SquCQ1YhWva_T6RXxRXMe4QwhhxhvR0rfFBRUZX4vmsvi9jaXuYfSph6DmQ9nBBNZpp4bb8q4MkIKPM-jk9lDGtJhD6e15hZvKWSUHU4rlL5f6nNiruOLdlIIyi05qyJDZDYMKh2pctJv8kvuqsEajele8sWqIcH16r4ofnz99v_9aPXz7sr2_e6g0JS2qGt4hjVvcItvWlHcWoBFagaqppVqYVoDBVgGzTBCiLbSWWcsUMpSBsh29KrZHXuPVTs7BjXke6ZWTfxM-PEoVktMDSI00R0SJ3CbT10QxgQQQg4zgrTAsc90euealG8FoWHcdzkjPfybXy0e_lxjXXGBGMsPHE0PwPxeISY4uasgiTZDlkRRjzmnTUJ6h7AjV-RoxgH3ug5FcHSF38uQIuTpCHh2R6z68HPK56un-_7aALPveQZBR50tqMC7ko2dd3H9a_AF59c_T</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3118836638</pqid></control><display><type>article</type><title>Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma</title><source>PubMed Central Free</source><source>ScienceDirect (Online service)</source><creator>Ouyang, Yonghao ; Liu, Pengpeng ; Chu, Lihua ; Xiao, Yi ; Zhu, Hong ; Qiang hao ; Zhang, Caihua</creator><creatorcontrib>Ouyang, Yonghao ; Liu, Pengpeng ; Chu, Lihua ; Xiao, Yi ; Zhu, Hong ; Qiang hao ; Zhang, Caihua</creatorcontrib><description>Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy. 117 patients with invasive IPMC were included in The Surveillance, Epidemiology, and End Results (SEER) database. These patients were subsequently divided into two subgroups according to whether they received chemotherapy or not: the non-chemotherapy group (patients who did not receivechemotherapy, N = 58), the chemotherapy group (patients who received chemotherapy, N = 59). The overall survival (OS) and cancer specific survival (CSS) of two treatment groups were evaluated. Before adjusting for pathology grade, the Kaplan-Meier analysis showed that the difference of survival time is not significant between non-chemotherapy group and chemotherapy group (P &gt; 0.05), but the land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group (P &lt; 0.05). After adjust the pathology grade, survival time of the chemotherapy group is significantly longer than non-chemotherapy group (P &lt; 0.05). Univariate and multivariate Cox regression showed that chemotherapy was an independent prognostic protective factor for invasive IPMC (P &lt; 0.05). Land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group in N1-N2 subgroup (P &lt; 0.05). Chemotherapy is an independent protective factor IPMC, especially reducing the risk of short-term death for IPMC patients with lymph node metastasis.</description><identifier>ISSN: 2405-8440</identifier><identifier>EISSN: 2405-8440</identifier><identifier>DOI: 10.1016/j.heliyon.2024.e38430</identifier><identifier>PMID: 39430496</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Chemotherapy ; Invasive intraductal papillary-mucinous carcinoma (IPMC) ; Prognostic</subject><ispartof>Heliyon, 2024-10, Vol.10 (19), p.e38430, Article e38430</ispartof><rights>2024 The Authors</rights><rights>2024 The Authors.</rights><rights>2024 The Authors 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3270-68b0c17170f7438bfee69caea43f3c9d79ed1fae5f5922cfe7f5ff5a0d35eafb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489152/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S2405844024144611$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3549,27924,27925,45780,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39430496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ouyang, Yonghao</creatorcontrib><creatorcontrib>Liu, Pengpeng</creatorcontrib><creatorcontrib>Chu, Lihua</creatorcontrib><creatorcontrib>Xiao, Yi</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Qiang hao</creatorcontrib><creatorcontrib>Zhang, Caihua</creatorcontrib><title>Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma</title><title>Heliyon</title><addtitle>Heliyon</addtitle><description>Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy. 117 patients with invasive IPMC were included in The Surveillance, Epidemiology, and End Results (SEER) database. These patients were subsequently divided into two subgroups according to whether they received chemotherapy or not: the non-chemotherapy group (patients who did not receivechemotherapy, N = 58), the chemotherapy group (patients who received chemotherapy, N = 59). The overall survival (OS) and cancer specific survival (CSS) of two treatment groups were evaluated. Before adjusting for pathology grade, the Kaplan-Meier analysis showed that the difference of survival time is not significant between non-chemotherapy group and chemotherapy group (P &gt; 0.05), but the land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group (P &lt; 0.05). After adjust the pathology grade, survival time of the chemotherapy group is significantly longer than non-chemotherapy group (P &lt; 0.05). Univariate and multivariate Cox regression showed that chemotherapy was an independent prognostic protective factor for invasive IPMC (P &lt; 0.05). Land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group in N1-N2 subgroup (P &lt; 0.05). Chemotherapy is an independent protective factor IPMC, especially reducing the risk of short-term death for IPMC patients with lymph node metastasis.</description><subject>Chemotherapy</subject><subject>Invasive intraductal papillary-mucinous carcinoma (IPMC)</subject><subject>Prognostic</subject><issn>2405-8440</issn><issn>2405-8440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNqFUk1v1DAQjRCIVqU_AZQjl2z9ESf2qaoqPlaqxAXOlmOPG6-SONjOor3zw3HYbemeOHk0fvNm5s0rivcYbTDCzc1u08PgDn7aEETqDVBeU_SquCQ1YhWva_T6RXxRXMe4QwhhxhvR0rfFBRUZX4vmsvi9jaXuYfSph6DmQ9nBBNZpp4bb8q4MkIKPM-jk9lDGtJhD6e15hZvKWSUHU4rlL5f6nNiruOLdlIIyi05qyJDZDYMKh2pctJv8kvuqsEajele8sWqIcH16r4ofnz99v_9aPXz7sr2_e6g0JS2qGt4hjVvcItvWlHcWoBFagaqppVqYVoDBVgGzTBCiLbSWWcsUMpSBsh29KrZHXuPVTs7BjXke6ZWTfxM-PEoVktMDSI00R0SJ3CbT10QxgQQQg4zgrTAsc90euealG8FoWHcdzkjPfybXy0e_lxjXXGBGMsPHE0PwPxeISY4uasgiTZDlkRRjzmnTUJ6h7AjV-RoxgH3ug5FcHSF38uQIuTpCHh2R6z68HPK56un-_7aALPveQZBR50tqMC7ko2dd3H9a_AF59c_T</recordid><startdate>20241015</startdate><enddate>20241015</enddate><creator>Ouyang, Yonghao</creator><creator>Liu, Pengpeng</creator><creator>Chu, Lihua</creator><creator>Xiao, Yi</creator><creator>Zhu, Hong</creator><creator>Qiang hao</creator><creator>Zhang, Caihua</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241015</creationdate><title>Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma</title><author>Ouyang, Yonghao ; Liu, Pengpeng ; Chu, Lihua ; Xiao, Yi ; Zhu, Hong ; Qiang hao ; Zhang, Caihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3270-68b0c17170f7438bfee69caea43f3c9d79ed1fae5f5922cfe7f5ff5a0d35eafb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chemotherapy</topic><topic>Invasive intraductal papillary-mucinous carcinoma (IPMC)</topic><topic>Prognostic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ouyang, Yonghao</creatorcontrib><creatorcontrib>Liu, Pengpeng</creatorcontrib><creatorcontrib>Chu, Lihua</creatorcontrib><creatorcontrib>Xiao, Yi</creatorcontrib><creatorcontrib>Zhu, Hong</creatorcontrib><creatorcontrib>Qiang hao</creatorcontrib><creatorcontrib>Zhang, Caihua</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Heliyon</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ouyang, Yonghao</au><au>Liu, Pengpeng</au><au>Chu, Lihua</au><au>Xiao, Yi</au><au>Zhu, Hong</au><au>Qiang hao</au><au>Zhang, Caihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma</atitle><jtitle>Heliyon</jtitle><addtitle>Heliyon</addtitle><date>2024-10-15</date><risdate>2024</risdate><volume>10</volume><issue>19</issue><spage>e38430</spage><pages>e38430-</pages><artnum>e38430</artnum><issn>2405-8440</issn><eissn>2405-8440</eissn><abstract>Whether chemotherapy can improve the prognosis of invasive intraductal papillary-mucinous carcinoma (IPMC) still remains unclear. The aim of this study is to observe the difference in survival time of patients with invasive IPMC receiving or not receiving chemotherapy. 117 patients with invasive IPMC were included in The Surveillance, Epidemiology, and End Results (SEER) database. These patients were subsequently divided into two subgroups according to whether they received chemotherapy or not: the non-chemotherapy group (patients who did not receivechemotherapy, N = 58), the chemotherapy group (patients who received chemotherapy, N = 59). The overall survival (OS) and cancer specific survival (CSS) of two treatment groups were evaluated. Before adjusting for pathology grade, the Kaplan-Meier analysis showed that the difference of survival time is not significant between non-chemotherapy group and chemotherapy group (P &gt; 0.05), but the land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group (P &lt; 0.05). After adjust the pathology grade, survival time of the chemotherapy group is significantly longer than non-chemotherapy group (P &lt; 0.05). Univariate and multivariate Cox regression showed that chemotherapy was an independent prognostic protective factor for invasive IPMC (P &lt; 0.05). Land-mark analysis showed that short-term death risk of the chemotherapy group is significantly lower than non-chemotherapy group in N1-N2 subgroup (P &lt; 0.05). Chemotherapy is an independent protective factor IPMC, especially reducing the risk of short-term death for IPMC patients with lymph node metastasis.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39430496</pmid><doi>10.1016/j.heliyon.2024.e38430</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2405-8440
ispartof Heliyon, 2024-10, Vol.10 (19), p.e38430, Article e38430
issn 2405-8440
2405-8440
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_c0c802a938ba4342a5909e2d0d9879d5
source PubMed Central Free; ScienceDirect (Online service)
subjects Chemotherapy
Invasive intraductal papillary-mucinous carcinoma (IPMC)
Prognostic
title Is chemotherapy beneficial? A retrospective study of chemotherapy in patients with invasive intraductal papillary-mucinous carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A16%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20chemotherapy%20beneficial?%20A%20retrospective%20study%20of%20chemotherapy%20in%20patients%20with%20invasive%20intraductal%20papillary-mucinous%20carcinoma&rft.jtitle=Heliyon&rft.au=Ouyang,%20Yonghao&rft.date=2024-10-15&rft.volume=10&rft.issue=19&rft.spage=e38430&rft.pages=e38430-&rft.artnum=e38430&rft.issn=2405-8440&rft.eissn=2405-8440&rft_id=info:doi/10.1016/j.heliyon.2024.e38430&rft_dat=%3Cproquest_doaj_%3E3118836638%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3270-68b0c17170f7438bfee69caea43f3c9d79ed1fae5f5922cfe7f5ff5a0d35eafb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3118836638&rft_id=info:pmid/39430496&rfr_iscdi=true